Skip to main content
. 2023 Feb 23;11:1065938. doi: 10.3389/fpubh.2023.1065938

Table 2.

Comparison of estimated mean depressive symptom scores (PHQ-2) for mid-March to mid-September 2019–2022.

Calendar weeks cw 11-37 2019 cw 11-37 2020 cw 11-37 2019 vs.cw 11-37 2020 cw 11-37 2021 cw 11-37 2019 vs.cw 11-37 2021 cw 11-37 2020 vs.cw 11-37 2021 cw 11-24 2022 cw 11-37 2019 vs.cw 11-24 2022 cw 11-37 2020 vs.cw 11-24 2022 cw 11-37 2021 vs.cw 11-24 2022
Outcome Mean 95%-CI Mean 95%-CI P -value Mean 95%-CI P -values Mean 95%-CI P -values
Total 0.96 0.90 1.01 0.86 0.81 0.90 0.007 1.11 1.05 1.17 0.000 0.000 1.26 1.20 1.32 0.000 0.000 0.000
Sex
Male 0.93 0.85 1.01 0.78 0.71 0.85 0.006 1.00 0.92 1.09 0.181 0.000 1.19 1.10 1.28 0.000 0.000 0.003
Female 1.00 0.92 1.08 0.94 0.87 1.01 0.291 1.22 1.13 1.32 0.001 0.000 1.33 1.26 1.41 0.000 0.000 0.084
Age
18–29 1.12 0.91 1.33 1.10 0.95 1.26 0.917 1.30 1.06 1.54 0.256 0.172 1.35 1.18 1.52 0.089 0.034 0.733
30–44 0.89 0.75 1.03 0.77 0.64 0.89 0.205 1.21 1.02 1.40 0.007 0.000 1.09 0.95 1.23 0.044 0.001 0.302
45–64 1.09 0.98 1.19 0.91 0.82 1.00 0.011 1.07 0.96 1.17 0.797 0.026 1.37 1.26 1.47 0.000 0.000 0.000
65+ 0.80 0.71 0.89 0.73 0.65 0.81 0.267 0.94 0.86 1.02 0.022 0.000 1.15 1.07 1.24 0.000 0.000 0.000
Level of education
Low 1.20 1.05 1.35 1.02 0.91 1.14 0.074 1.33 1.16 1.50 0.264 0.005 1.45 1.31 1.58 0.015 0.000 0.283
Middle 0.91 0.84 0.98 0.81 0.75 0.87 0.033 1.02 0.94 1.09 0.038 0.000 1.20 1.12 1.27 0.000 0.000 0.001
High 0.68 0.62 0.74 0.66 0.58 0.74 0.784 0.87 0.81 0.94 0.000 0.000 0.98 0.92 1.04 0.000 0.000 0.014

Time periods: mid-March to mid-September 2019–2021 (CW 11-37) and mid-March to mid-June (CW 11-24) 2022. Calculation of estimates as well as p-values for comparisons between time periods detailed in section 2.4.2 in Methods. Estimates for each sociodemographic characteristic subgroup are standardized for the respective other two characteristics (e.g., estimates for women standardized for age and level of education). p-values for pairwise comparisons only reported in case of significant joint tests (Supplementary Table A1).